Opens in new windowAs we look ahead to 2025, the pharmaceutical industry is poised for transformation once again. The increasing integration of AI across all facets of the industry is set to revolutionize drug discovery, development, patient care and commercialization. The topic is peppered within chapters to reflect industry leader thinking on implementation within their respective wheelhouses.
The industry must also navigate the very tangible landscape of geopolitical risk. Regional instability along with new regulation could disrupt supply chains and impact global operations, necessitating robust risk management strategies. With global elections now in the 2024 rear view mirror, can the pharma and medtech markets turn toward stable growth that has stagnated marquee M&A in 2024?
Therapy areas such as cancer and obesity are driving this growth. Advances in oncology are particularly noteworthy, with innovative treatments offering new hope for patients through radiopharmaceuticals, combinations, and neoadjuvant therapies. The focus on obesity is intensifying and pharma is investing in the clinic to find new ways of tackling this age old problem. Expect to see more study results and patient options launched in 2025.
Concurrently, the medtech sector is undergoing substantial restructuring. Companies are optimizing their operations and exploring new business models, to remain competitive and meet the demands of a rapidly changing health care environment.
In this issue, we delve into these trends and more. Our coverage includes industry rankings such as the Scrip 100, Generics Bulletin Top 50 and Scrip Asia 100.
Join us as we explore what 2025 has in store for pharma and medtech as these dynamic industries grow and confront global challenges.
Jo Shorthouse
Executive Editor
